Mereo BioPharma Group plc provided a corporate update, highlighting ongoing analyses of data from the Orbit and Cosmic Phase 3 studies of setrusumab (UX143) for osteogenesis imperfecta $(OI)$ to determine the potential path forward for the program. The company reported a cash balance of approximately $41 million as of December 31, 2025, and updated its runway guidance to mid-2027 following reductions and delays in pre-commercial and manufacturing activities related to setrusumab. Mereo continues to assess the totality of the Phase 3 trial data and is considering potential interactions with regulators. For its alvelestat (MPH-966) program in alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD), Mereo is preparing for a global Phase 3 pivotal study. The anticipated trial will enroll approximately 220 patients and evaluate alvelestat over an 18-month period. The primary efficacy endpoint for U.S. approval is the St. George's Respiratory Questionnaire (SGRQ) Total Score, while lung density measured by CT scan will serve as the primary endpoint for potential European approval. The company is also in active discussions with potential partners for the Phase 3 development and commercialization of alvelestat.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mereo BioPharma Group plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9623649-en) on January 12, 2026, and is solely responsible for the information contained therein.